|
gptkbp:instanceOf
|
gptkb:receptor_tyrosine_kinase
gptkb:drug
antineoplastic agent
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
2002
|
|
gptkbp:ATCCode
|
L01EB01
|
|
gptkbp:bioavailability
|
~60%
|
|
gptkbp:brand
|
gptkb:Iressa
|
|
gptkbp:CASNumber
|
184475-35-2
|
|
gptkbp:chemicalFormula
|
C22H24ClFN4O3
|
|
gptkbp:contraindication
|
severe hepatic impairment
hypersensitivity to gefitinib
|
|
gptkbp:developedBy
|
gptkb:AstraZeneca
|
|
gptkbp:discoveredBy
|
gptkb:AstraZeneca
|
|
gptkbp:drugInteraction
|
gptkb:rifampicin
gptkb:phenytoin
gptkb:warfarin
gptkb:ketoconazole
gptkb:St._John's_wort
|
|
gptkbp:eliminationHalfLife
|
41 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:genericName
|
yes
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Gefitinib
|
|
gptkbp:KEGGID
|
D00554
|
|
gptkbp:legalStatus
|
expired
prescription only
|
|
gptkbp:mechanismOfAction
|
EGFR tyrosine kinase inhibition
|
|
gptkbp:MedlinePlusID
|
a603010
|
|
gptkbp:MeSH_ID
|
C477489
|
|
gptkbp:metabolism
|
gptkb:CYP2D6
gptkb:CYP3A4
|
|
gptkbp:molecularWeight
|
446.9 g/mol
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:proteinBinding
|
90%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL941
123631
DB00317
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
vomiting
diarrhea
anorexia
rash
interstitial lung disease
|
|
gptkbp:target
|
gptkb:epidermal_growth_factor_receptor
|
|
gptkbp:UNII
|
S2A4O4F3EC
|
|
gptkbp:usedFor
|
gptkb:non-small_cell_lung_cancer
|
|
gptkbp:bfsParent
|
gptkb:Non-Small_Cell_Lung_Cancer
|
|
gptkbp:bfsLayer
|
6
|